Literature DB >> 28655060

Biomarkers and Surrogate Endpoints in Uveitis: The Impact of Quantitative Imaging.

Alastair K Denniston1, Pearse A Keane2, Sunil K Srivastava3.   

Abstract

Purpose: Uveitis is a major cause of sight loss across the world. The reliable assessment of intraocular inflammation in uveitis ('disease activity') is essential in order to score disease severity and response to treatment. In this review, we describe how 'quantitative imaging', the approach of using automated analysis and measurement algorithms across both standard and emerging imaging modalities, can develop objective instrument-based measures of disease activity.
Methods: This is a narrative review based on searches of the current world literature using terms related to quantitative imaging techniques in uveitis, supplemented by clinical trial registry data, and expert knowledge of surrogate endpoints and outcome measures in ophthalmology.
Results: Current measures of disease activity are largely based on subjective clinical estimation, and are relatively insensitive, with poor discrimination and reliability. The development of quantitative imaging in uveitis is most established in the use of optical coherence tomographic (OCT) measurement of central macular thickness (CMT) to measure severity of macular edema (ME). The transformative effect of CMT in clinical assessment of patients with ME provides a paradigm for the development and impact of other forms of quantitative imaging. Quantitative imaging approaches are now being developed and validated for other key inflammatory parameters such as anterior chamber cells, vitreous haze, retinovascular leakage, and chorioretinal infiltrates. Conclusions: As new forms of quantitative imaging in uveitis are proposed, the uveitis community will need to evaluate these tools against the current subjective clinical estimates and reach a new consensus for how disease activity in uveitis should be measured. The development, validation, and adoption of sensitive and discriminatory measures of disease activity is an unmet need that has the potential to transform both drug development and routine clinical care for the patient with uveitis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28655060     DOI: 10.1167/iovs.17-21788

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

1.  Grading Anterior Chamber Inflammation with Anterior Segment Optical Coherence Tomography: An Overview.

Authors:  Morgan Maring; Steven S Saraf; Marian Blazes; Sumit Sharma; Sunil Srivastava; Kathryn L Pepple; Cecilia S Lee
Journal:  Ocul Immunol Inflamm       Date:  2022-02-17       Impact factor: 3.728

2.  Improving quick and accurate diagnosis of childhood JIA-uveitis from a pediatric rheumatology perspective.

Authors:  Jackeline Rodriguez-Smith; Steven Yeh; Sheila Angeles-Han
Journal:  Expert Rev Ophthalmol       Date:  2020-03-12

Review 3.  Under-utilisation of reproducible, child appropriate or patient reported outcome measures in childhood uveitis interventional research.

Authors:  Ameenat L Solebo; Robert J Barry; Pearse A Keane; Jugnoo S Rahi; Alastair K Denniston
Journal:  Orphanet J Rare Dis       Date:  2019-06-06       Impact factor: 4.123

4.  Instrument-based tests for quantifying aqueous humour protein levels in uveitis: a systematic review protocol.

Authors:  Thomas W McNally; Xiaoxuan Liu; Sophie Beese; Pearse A Keane; David J Moore; Alastair K Denniston
Journal:  Syst Rev       Date:  2019-11-26

5.  Instrument-based Tests for Measuring Anterior Chamber Cells in Uveitis: A Systematic Review.

Authors:  Xiaoxuan Liu; Ameenat L Solebo; Livia Faes; Sophie Beese; Tasanee Braithwaite; Matthew E Round; Jesse Panthagani; Aditya U Kale; Thomas W McNally; Didar Abdulla; Pearse A Keane; David J Moore; Alastair K Denniston
Journal:  Ocul Immunol Inflamm       Date:  2019-08-16       Impact factor: 3.070

6.  OCT Assisted Quantification of Vitreous Inflammation in Uveitis.

Authors:  Xiaoxuan Liu; Aditya U Kale; Giovanni Ometto; Giovanni Montesano; Alice J Sitch; Nicholas Capewell; Charlotte Radovanovic; Nicholas Bucknall; Nicholas A V Beare; David J Moore; Pearse A Keane; David P Crabb; Alastair K Denniston
Journal:  Transl Vis Sci Technol       Date:  2022-01-03       Impact factor: 3.283

7.  Automated Quantification of Choriocapillaris Lesion Area in Patients With Posterior Uveitis.

Authors:  K Matthew McKay; Zhongdi Chu; Joon-Bom Kim; Alex Legocki; Xiao Zhou; Meng Tian; Marion R Munk; Ruikang K Wang; Kathryn L Pepple
Journal:  Am J Ophthalmol       Date:  2021-06-06       Impact factor: 5.258

Review 8.  Quantitative Assessment of Experimental Ocular Inflammatory Disease.

Authors:  Lydia J Bradley; Amy Ward; Madeleine C Y Hsue; Jian Liu; David A Copland; Andrew D Dick; Lindsay B Nicholson
Journal:  Front Immunol       Date:  2021-06-18       Impact factor: 7.561

9.  Optimizing OCT acquisition parameters for assessments of vitreous haze for application in uveitis.

Authors:  G Montesano; C M Way; G Ometto; H Ibrahim; P R Jones; R Carmichael; X Liu; T Aslam; P A Keane; D P Crabb; A K Denniston
Journal:  Sci Rep       Date:  2018-01-26       Impact factor: 4.379

10.  Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial.

Authors:  Athimalaipet V Ramanan; Andrew D Dick; Catherine Guly; Andrew McKay; Ashley P Jones; Ben Hardwick; Richard W J Lee; Matthew Smyth; Thomas Jaki; Michael W Beresford
Journal:  Lancet Rheumatol       Date:  2020-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.